Cargando…

Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey

PURPOSE: To evaluate the clinical and demographic aspects of off-label drug use applications for age-related macular degeneration (AMD) in Turkey. METHODS: Applications for off-label drug use in the treatment of AMD to the Turkish Medicines and Medical Devices Agency (TITCK) in 2018 were retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yilmaz, Mevlut, Citirik, Mehmet, Rahmanlar, Hanife, Alkan, Ali, Gursoz, Hakki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481980/ https://www.ncbi.nlm.nih.gov/pubmed/37680284 http://dx.doi.org/10.4103/joco.joco_323_22

Ejemplares similares

Off-label uses of Aflibercept, Ranibizumab and Dexamethasone implant for diabetic retinopathy in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2022)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab
por: Unsal, Erkan, et al.
Publicado: (2018)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
por: Urban, Beata, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration
por: Topal, Tuncay, et al.
Publicado: (2017)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview
por: Empeslidis, Theodoros, et al.
Publicado: (2019)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
por: Ferreira, Alberto, et al.
Publicado: (2015)

Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
por: Slean, Geraldine R., et al.
Publicado: (2016)

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia
por: Skelly, Adrian, et al.
Publicado: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman, Eric, et al.
Publicado: (2016)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis
por: Souied, Eric H., et al.
Publicado: (2016)

Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
Publicado: (2015)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
por: Tyagi, Pallavi, et al.
Publicado: (2018)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma, Keiko, et al.
Publicado: (2018)

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration
por: Kovacs, Attila, et al.
Publicado: (2018)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
Publicado: (2017)

Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept
por: Wons, Juliana, et al.
Publicado: (2017)

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
por: Gale, Richard P, et al.
Publicado: (2020)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
por: Haensli, Christof, et al.
Publicado: (2021)

Optical density changes of subretinal hyperreflective material in age-related macular degeneration after switching therapy from ranibizumab to aflibercept
por: Filik, Armagan, et al.
Publicado: (2022)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b6g7t128lgcj811r39r7sfrs2s